Cited by 69Nitric Oxide and Endothelin EffectsHeme Oxygenase-1 and Carbon MonoxideAtherosclerosis and Cardiovascular Diseases

Nitro-fatty acid inhibition of neointima formation after endoluminal vessel injury

Open access
Cole, Marsha P., Rudolph, Tanja K., Khoo, Nicholas K.H., Motanya, Uche N., Golin-Bisello, Franca, Wertz, Jeffrey W., Schopfer, Francisco J., Rudolph, Volker +8 more·2009·Circulation Research

Abstract

RATIONALE: Fatty acid nitroalkenes are endogenously generated electrophilic byproducts of nitric oxide and nitrite-dependent oxidative inflammatory reactions. Existing evidence indicates nitroalkenes support posttranslational protein modifications and transcriptional activation that promote the resolution of inflammation. OBJECTIVE: The aim of this study was to assess whether in vivo administration of a synthetic nitroalkene could elicit antiinflammatory actions in vivo using a murine model of vascular injury. METHODS AND RESULTS: The in vivo administration (21 days) of nitro-oleic acid (OA-NO(2)) inhibited neointimal hyperplasia after wire injury of the femoral artery in a murine model (OA-NO(2) treatment resulted in reduced intimal area and intima to media ratio versus vehicle- or oleic acid (OA)-treated animals,P<0.0001). Increased heme oxygenase (HO)-1 expression accounted for much of the vascular protection induced by OA-NO(2) in both cultured aortic smooth muscle cells and in vivo. Inhibition of HO by Sn(IV)-protoporphyrin or HO-1 small interfering RNA reversed OA-NO(2)-induced inhibition of platelet-derived growth factor-stimulated rat aortic smooth muscle cell migration. The upregulation of HO-1 expression also accounted for the antistenotic actions of OA-NO(2) in vivo, because inhibition of neointimal hyperplasia following femoral artery injury was abolished in HO-1(-/-) mice (OA-NO(2)-treated wild-type versus HO-1(-/-) mice, P=0.016). CONCLUSIONS: In summary, electrophilic nitro-fatty acids induce salutary gene expression and cell functional responses that are manifested by a clinically significant outcome, inhibition of neointimal hyperplasia induced by arterial injury.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circresaha.109.199075

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • NO2-FAs exert pleiotropic post-translational, anti-oxidant and anti-inflammatory effects that include inhibition of vascular smooth muscle proliferation and neointima formation after injury, cardioprotection, improved endothelial function, and activation of downstream NO signaling pathways.

    “NO2-FAs exert pleiotropic post-translational, anti-oxidant and anti-inflammatory effects[105,321,385] that include inhibition of vascular smooth muscle proliferation and neointima formation after injury, cardioprotection, improved endothelial function[94,386–390], and activation of downstream NO signaling pathways[385,389,391–394].”
  • In murine models of metabolic and inflammatory injury, fatty acid nitroalkene administration at nanomolar concentrations prevents restenosis after vessel injury.

    “Thus, in murine models of metabolic and inflammatory injury, fatty acid nitroalkene administration at nanomolar concentrations prevents restenosis after vessel injury (49), limits weight gain and loss of insulin sensitivity in murine models of metabolic syndrome (14), protects against ischemia-reperfusion injury (17,47,50), reduces plaque formation in a rodent model of atherosclerosis (51), and in”
  • OA-NO2 inhibits neointimal hyperplasia.

    “In the context of the vasculature, OA-NO2 inhibits neointimal hyperplasia19 and exerts vasorelaxation of preconstricted aortic rings20.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Cole, M. P., Rudolph, T. K., Khoo, N. K. H., Motanya, U. N., Golin-Bisello, F., Wertz, J. W., Schopfer, F. J., Rudolph, V., Woodcock, S. R., Bolisetty, S., Ali, M. S., Zhang, J., Chen, Y. E., Agarwal, A., Freeman, B. A., & Bauer, P. M.
Affiliations
  • University of Pittsburgh (US)
  • From the Departments of Pharmacology &amp; Chemical Biology (M.P.C., T.K.R., N.K.H.K., U.N.M., F.G.-B., F.J.S., V.R., S.R.W., M.S.A., B.A.F., P.M.B.) and Surgery (J.W.W., P.M.B.), University of Pittsburgh, Pa; Cardiovascular Center (J.Z., Y.E.C.), Department of Internal Medicine, University of Michigan, Ann Arbor; and Department of Medicine (S.B., A.A.), Nephrology Research and Training Center, Department of Biochemistry and Molecular Genetics, University of Alabama, Birmingham.
Venue
Circulation Research
Published
2009-11-06
Volume
105
Issue
10
Pages
965-972
ISSN
  • 0009-7330 (ISSN-L)
  • 1524-4571
OpenAlex
W2135949681
Cited by
69
References
32
Citations by year
2026: 1 · 2025: 1 · 2024: 2 · 2023: 1 · 2022: 1 · 2021: 5 · 2020: 4 · 2019: 4 · 2018: 7 · 2017: 6 · 2016: 5 · 2015: 5 · 2014: 5 · 2013: 7 · 2012: 3
FWCI
3.32
Type
journal article
Language
en
Open access
Locations
  • Circulation Research (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • American Heart Association
  • University of Pittsburgh
  • Deutsche Forschungsgemeinschaft (Ru 1472/1-1, 1472/1-1)
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute (HL 64937, R01HL064937, HL 58115, R37HL058115, R01HL058115, HL085134, R01HL085134, R01HL132550)
  • National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007052)
Topics
  • Health Sciences › Medicine › Physiology › Nitric Oxide and Endothelin Effects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heme Oxygenase-1 and Carbon Monoxide
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
Keywords
nitro-fatty acids, nitro-oleic acid, intimal hyperplasia, heme oxygenase-1, anti-inflammatory activity, platelet-derived growth factor, vascular inflammation, post-translational modification
MeSH terms
Animals, Cell Movement, Femoral Artery, Heme Oxygenase (Decyclizing), Inflammation, Nitric Oxide, Nitro Compounds, Oleic Acids, Oxidation-Reduction, Platelet-Derived Growth Factor, Up-Regulation, Gene Expression Regulation, Enzymologic, Tunica Intima, Mice, Knockout, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review